The attachment of the sugar D-N-acetylglucosamine (GlcNAc) with to specific serine and threonine residues on proteins is referred to as protein O-GlcNAcylation. O-GlcNAc transferase (OGT) is the enzyme responsible for carrying out the modification while O-GlcNAcase (OGA) reverses it. Protein O-GlcNAcylation has been implicated in a wide range of cellular processes including transcription, proteostasis and stress response. Dysregulation of O-GlcNAc has been linked to diabetes, cancer, neurodegenerative and cardiovascular disease. OGA has been proposed to be a drug target for the treatment of Alzheimer's and cardiovascular disease given that increased O-GlcNAc levels appear to exert a protective effect. The search for specific, potent and drug-like OGA inhibitors with bioavailability in the brain is therefore a field of active research, requiring orthogonal high-throughput assay platforms. Here we describe the synthesis of a novel probe for use in a fluorescence polarization based assay for the discovery of inhibitors of OGA. We show that the probe is suitable for use with both human OGA, as well as the orthologous bacterial counterpart from Clostridium perfringens, CpOGA, and the lysosomal hexosaminidases HexA/B. We structurally characterize CpOGA in complex with a ligand identified from a fragment library screen using this assay. The versatile synthesis procedure could be adapted for making fluorescent probes for the assay of other glycoside hydrolases.
Introduction
Protein O-GlcNAcylation is the dynamic and reversible modification of specific serine and threonine side chains on multitude of nucleocytoplasmic and mitochondrial proteins with a single β-Nacetylglucosamine residue 1 . The attachment of the sugar is catalyzed by the enzyme O-GlcNAc transferase (OGT) and its removal by O-GlcNAcase (OGA). Both OGT and OGA are essential enzymes in mice, with their loss resulting in lethality [2] [3] [4] . Protein O-GlcNAcylation is involved in various cellular processes including transcription [5] [6] [7] [8] , protein stability/degradation 9 , and stress response [10] [11] [12] ; in most these processes, however, the exact role of O-GlcNAcylation is yet to be deciphered.
Dysregulation of O-GlcNAc cycling, associated with malfunctions in the production and activity of the processing enzymes, is a feature of pathological conditions such as diabetes, cancer, Alzheimer's disease and cardiovascular disease 1, 9, [13] [14] [15] .
The structural characterization of bacterial OGAs and more recently human OGA gave insights into the binding mode of O-GlcNAc proteins [16] [17] [18] [19] [20] . Schimpl et al. showed that glycosylated substrate peptides bind in a conserved groove in a similar conformation and orientation, adopting a "V"-shaped conformation with the residue side chains pointing away from the active site, explaining how a single enzyme can recognize > 1000 different substrates 16 . Inspection of the structures revealed that the peptide backbone forms interactions with OGA, in the -4 through the +3 position surrounding the OGlcNAc site 16 . Additional hydrophobic interactions are formed by residues in the -1 and -2 position and a surface exposed Tyr 189 in CpOGA, which is conserved in the human OGA (Tyr 69 ) 16, 17 . Studies revealed that mutation of Tyr69 in human OGA leads to a significant reduction in catalytic activity on the substrate analogue 4-methylumbelliferyl-β-D-N-acetylglucosaminide (4MU-GlcNAc)
17
.
Structural studies of human OGT [21] [22] [23] and bacterial orthologues of OGA 24, 25 have allowed the development of inhibitors [26] [27] [28] [29] [30] [31] [32] [33] to study the function of these enzymes at the molecular and cellular level. In the case of OGA, potent, cell penetrant inhibitors exist [29] [30] [31] [32] [33] , and have been used for the identification of OGA as a potential drug target for the treatment of Alzheimer's disease (AD) and cardiovascular disease [34] [35] [36] . Hyperphosphorylation of the protein tau resulting in the formation of neurofibrillary tangles (NFTs) in AD leading to neuronal loss can be slowed by increasing OGlcNAcylation, which stabilizes tau, preventing its aggregation
34
. This study was performed using mice fed with the OGA inhibitor Thiamet G 40, 41 . Also, as a solution based technique, an FP assay is more amenable to high throughput formats. While the OGA activity assay based on the hydrolysis of the fluorescent substrate 4MU-GlcNAc provides a method for the discovery of OGA inhibitors 24, 42 , the measurement of inhibition constants for potent inhibitors requires long incubations periods (e.g. ~7 h for CpOGA and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 GlcNAcstatin C)
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. An advantage of an FP based OGA assay is direct measurement of binding rather than loss of activity, reducing assay length. The main limiting factor in the development of an FP assay is the requirement for a tailor-made fluorescent ligand with high affinity to the protein/receptor under study, which is what we report here. 
Results and Discussion
Previously, we established a robust synthetic approach to a family of highly potent and selective OGA inhibitors, built on 8-alkylamido 2-phenethyl substituted bicyclic sugar-imidazole scaffold (GlcNAcstatins)
43
. Here we disclose the synthesis of a fluorescently tagged derivative of the potent OGA inhibitor GlcNAcstatin B 1 created by the replacement of the 2-phenethyl group of the parent molecule with aminopropyl spacer labeled with FITC (hereafter referred to as GlcNAcstatin BF 2 ( Fig.   1) ). We also report a novel FP displacement assay using GlcNAcstatin BF as a fluorescent tracer to measure the binding affinities of existing inhibitors to the bacterial OGA from Clostridium perfringens, CpOGA, as well as human OGA (hOGA).
We initially devised a concise synthetic scheme to access GlcNAcstatin BF 2 (Scheme 1). We scheduled the chemoselective installation of a fluorescent tag onto the derivative 3 bearing the requisite aminopropyl handle that supports the final steps in synthesis of the target compound. To reach 3 we devised a novel synthetic approach for the construction of the 8-alkylamido 2-substituted sugar-imidazole 4 by reversing the order in which the corresponding substituents would be introduced into the target molecule as compared to the published approach
. Previously, the intermediate 6 was prepared by regioselective mono-deiodination of the diiododerivative 6a, which in turn was the product of a challenging bis-iodination (8 eq of NIS, 85 °C, 36 h) of the bicyclic sugar-imidazole 6b. The latter process was found to be unsuitable for upscaling, resulting in formation of varying amounts of the triply iodinated (ortho position in the p-methoxybenzyl (PMB) group) product, depending on the quality of NIS used. As an alternative route to intermediate 6, we decided to reinvestigate the cyclization of the linear 4,5-diiodoimidazole 7, which was previously found to be inert in a triflic anhydride mediated process 43 (Scheme 2). We assumed that the decreased pK a of the imidazole moiety in 7 would facilitate intramolecular reactivity under Mitsunobu N-alkylation conditions, giving the bicyclic sugar imidazole 6a directly. The intermolecular Mitsunobu N-alkylation reaction of imidazoles bearing electron-withdrawing substituents with different alcohols, including secondary, has several precedents in the literature 44, 45 .
Furthermore, Mitsunobu type cyclization of structurally similar sugar-derived 1,4-diols was consistently used for the synthesis of C-nucleosides including C2-imidazole and benzimidazole . In our hands, reaction of the linear precursor 7 under standard Mitsunobu conditions (PPh 3 , DIAD, 65 °C) resulted in formation of the expected known bicyclic product 6a in excellent yield (Scheme 2). The reaction was shown to be equally applicable to multi-gram scale preparations.
Taken together, the novel intramolecular Mitsunobu N-alkylation of 7 in conjunction with the proven highly efficient regioselective mono-deiodination of 6a represents a streamlined (and more economic) access to the key 2-iodoimidazole 6 that supersedes the triflic anhydride mediated cyclization/bisiodination sequence of the former approach
We have previously documented the hydrolytic stability of the BDA group in the GlcNAc-imidazoles
. Now we reveal that this phenomenon also works for neutral glycoimidazoles to introduce useful orthogonality towards acidolysis between PMB and BDA groups. Indeed, using the standard conditions for the deprotection of the PMB group (aqueous 90% TFA in DCM 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 pot global removal of the protecting groups in
(without purification) treated with a slight excess of FITC in DMF to furnish the fluorescently tagged product 2 (Scheme 2). The reaction mixture was directly purified by reverse phase flash chromatography on a C18 column and the product was re-purified to homogeneity by HPLC to afford the desired GlcNAcstatin BF in 65% yield over the three-step sequence.
We next wanted to assess the use of GlcNAcstatin BF with CpOGA and hOGA in an FP assay.
GlcNAcstatin BF bound to CpOGA with a K d of 0.5 ± 0.2 nM (Fig. 2a) and to hOGA with a K d of 143 ± 29 nM (Fig. 2b) . We then used GlcNAcstatin BF in displacement assays to measure the K d of the inhibitors GlcNAcstatin B and GlcNAcstatin G. Consistent with previous reports 32, 33 , GlcNAcstatin B was a better binder of CpOGA with a K i of 6.6 nM versus 16.3 nM for GlcNAcstatin G (Fig. 2c ). For hOGA, however, the K i obtained for GlcNAcstatin B was 23.2 nM and for GlcNAcstatin G, it was 21.4 nM (Fig. 2d) . The absolute K i values obtained for these inhibitors are not consistent with previously reported K i values obtained using the 4MU-NAG based activity assay 32, 33 . In addition to the variability expected from using different methods, this could be due to the differences in the assay buffer and pH used or the different N-terminal truncation of the construct used in this study. Dorfmueller et al., used the McIlvaine buffer system at pH 5.7/7.3
32, 33
, while here we use Tris buffered saline (TBS) at pH 7.5. The K i values obtained with the FP assay for the binding of CpOGA to GlcNAcstatin G and another potent OGA inhibitor Thiamet G 30 are consistent with those obtained using surface plasmon resonance (SPR) performed using the same assay buffer ( Supplementary Fig. S1 ); the binding affinity of hOGA for Thiamet G using the FP assay is shown in Supplementary Fig. S2 . These proofof-concept experiments establish the fluorescence polarization displacement assay using GlcNAcstatin BF as a convenient method for evaluating affinity of OGA inhibitors. To expand the applicability of the suggested assay system for the high-throughput screening of custom compound libraries, we decided to evaluate the Maybridge Ro3 1000 fragment library towards
CpOGA as a target. This library consists of fragments that adhere to the 'rule of three' (Ro3) (molecular weight ≤ 300 Da, no more than 3 hydrogen bond donors/acceptors, cLogP ≤ 3). The screen was performed under experimental conditions matching those used in the displacement of GBF by Thiamet G and GlcNAcstatin G (Supplementary material Fig. S3 ). (Fig. 3B) . 5TFD binds proximal to the active site pocket, forming hydrophobic stacking interactions with Tyr 189 (Fig 3B) . Additionally, the secondary amine of 5TFD forms a hydrogen bond with the backbone carbonyl oxygen of Asp 401 (Fig. 3B) . Tyr 189 has been previously identified to be important for substrate binding, forming hydrophobic interactions with the substrate peptide backbones
16
. When compared to a structure of CpOGA in complex with GlcNAcstatin F (Fig. 3 C, GlcNAcstatin BF may not only be useful to measure the binding of ligands to OGA, but also to enzymes of related glycoside hydrolase families such as GH20, to which human HexA/B belong. This is because GlcNAcstatin B itself, while potent, is not a selective inhibitor of OGA 32 and also targets HexA/HexB. We were able to determine an apparent K d of ~ 4 µM (Supplementary Material Figure 4) for GlcNAcstatin BF to HexA/B isolated from bovine kidneys. HexA/HexB have recently been 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 explored as targets for enzyme enhancement therapy to treat the lysosomal storage diseases TaySachs and Sandhoff disease 53 and an FP based assay offers an alternative to activity assays for the screening of fragments/compounds that bind to these proteins.
Here we have reported the design and synthesis of the novel fluorescent probe GlcNAcstatin BF to support miniaturized OGA high-throughput assays. To synthesize the target compound we CpOGA in complex with a binder identified in the screen and were able to show that it binds to Tyr189, an important residue for substrate binding. 
58
. Ligand topology was generated using PRODRG
59
. X-ray diffraction data collection and structure refinement statistics can be found in the supplementary material (Supplementary Material   Table 3 ).
Fluorescence Polarization
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Accession codes
The atomic coordinates and structure factors have been deposited in the Protein Data Bank 61 under the accession code 5OXD.
Supporting information
The Supporting Information, including synthetic procedures and spectral data for all new compounds, methods, figures and tables as well as the compound characterization checklist and the validation report of the deposited structure are available free of charge via the Internet.
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